Business Context and Reporting Period
Company: Ocular Therapeutix, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 28, 2022
Reporting Period: The filing announces financial results for the quarter and full year ended December 31, 2021.
Key Financial Metrics
The provided text serves as a cover sheet and does not contain specific financial data points. The actual results are referenced in an attached press release (Exhibit 99.1). Consequently, the following metrics are not available in this text:
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not provide specific numerical comparisons or material changes versus prior periods. It only confirms the announcement of results for the period ended December 31, 2021.
Guidance, Outlook, and Risks
Management Commentary: The text states that the full press release containing results is furnished as Exhibit 99.1 and incorporated by reference.
Legal Disclaimer: The information in this 8-K, including the press release, is furnished to comply with Item 2.02 and is not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it subject to the liabilities of that section.
Guidance and Risks: No specific guidance, outlook, or risk factors are detailed in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 28, 2022) for actual revenue, net loss, and cash position figures.
- Verify the specific details of the "Results of Operations" referenced in Item 2.02, as they are not embedded in the cover text.
- Confirm the company's status as an emerging growth company (indicated by a checkmark in the filing) and its election regarding extended transition periods for accounting standards.